Table 1.
Association between PHLPP2 expression and clinicopathological characteristics in 134 NSCLC patients
| PHLPP2 expression | ||||
|---|---|---|---|---|
| All patients | High (%) | Low (%) | ||
| Variable | (n = 134) | (n = 47) | (n = 87) | P‐value |
| Gender | ||||
| Male | 88 | 34 (72.3) | 54 (62.1) | 0.232 |
| Female | 46 | 13 (27.7) | 33 (37.9) | – |
| Age (years) | ||||
| <60 | 90 | 28 (59.6) | 62 (71.3) | 0.169 |
| ≥60 | 44 | 19 (40.4) | 25 (28.7) | – |
| Differentiation | ||||
| Well | 4 | 2(44.7) | 2(44.8) | 0.838† |
| Moderate | 65 | 23(48.9) | 42(48.3) | – |
| Poor | 65 | 22(6.4) | 43(6.9) | – |
| pTNM stage | ||||
| I | 72 | 31 (66.0) | 41 (47.1) | 0.096 |
| II | 23 | 7 (14.9) | 16 (18.4) | – |
| III | 39 | 9 (19.1) | 30 (34.5) | – |
| pT classification | ||||
| T1 | 42 | 17 (36.2) | 25 (28.7) | 0.215† |
| T2 | 83 | 25 (53.2) | 58 (66.7) | – |
| T3/4 | 9 | 5 (10.6) | 4 (4.6) | – |
| Lymph node metastasis | ||||
| Present | 83 | 37 (78.7) | 46 (52.9) | 0.003* |
| Absent | 51 | 10 (21.3) | 41 (47.1) | – |
*
P < 0.05 was considered statistically significant.
†
The Fisher's exact test.
NSCLC, non‐small cell lung cancer; pT, pathological tumor; pTNM, pathological tumor node metastasis.